 |
|
|
Investor Relations
|
Cytograft Tissue Engineering is a privately held corporation.
Cytograft is not currently raising capital.
 |
|
|
|
|
For investor updates, please login here
|
|
|
|
|
Market Profiles
|
Lifeline is targeted at three distinct patient populations; A-V shunts for hemodialysis patients, peripheral bypass grafts for lower limb amputation candidates, and coronary artery bypass grafts for coronary bypass revision patients. Collectively, these markets represent over $5 billion annually in the U.S. alone.
|
AV-Shunt
The vast majority of End Stage Renal Disease (ESRD) patients are treated with hemodialysis.
Hemodialysis requires vascular access through a permanent A-V fistula (where native veins are re-routed to connect to a native artery) or A-V shunt (where a synthetic conduit shunts arterial blood flow directly to the venous return).
Twenty-five percent of the total cost to treat ESRD is directly attributed to vascular access. There are currently over 300,000 ESRD patients in the U.S., and this patient population is growing by ~10% annually. Risk factors for ESRD (such as diabetes) are also growing, suggesting that the vascular access market for ESRD/hemodialysis patients will continue to grow.
|
Peripheral Bypass
Each year, over 130,000 lower limb amputations are performed due to poor vascularization.
Although studies demonstrate that revascularization is both cost effective and improves patient quality of life, lack of suitable small diameter graft material prohibits many of these patients from revascularization options.
Like ESRD, the primary risk factor for lower limb amputation is diabetes, a disease which now afflicts an estimated 21 million Americans.
With the increase in incidence of diabetes and other cardiovascular risk factors, the market for lower limb revascularization is likely to continue to grow.
|
Coronary Artery Bypass
Over 600,000 coronary artery grafts are placed each year in the United States.
About 20% of these procedures are revisions (secondary procedures).
Due to previous harvest or disease progress, suitable native vessels may not be available for these revision candidates.
50,000-100,000 revision candidates die annually in the United States due to lack of suitable graft vessels.
This population is likely to increase, following 10-12 years behind the explosive growth in primary procedures in the late 1980’s and 1990’s.
Cytograft Tissue Engineering’s Lifeline™ technology will be applied to this market as soon as efficacy is demonstrated in the less critical peripheral circulation.
|
|